In the study, scientists identified several downregulators that selectively suppress inflammatory signaling pathways.

The new drug downregulates the receptor that causes inflammation.

Researchers observed that downregulating the receptor significantly improved the patient's response to therapy.

The researchers found that the gene was downregulated after treatment.

Prolonged exposure to high hormone levels can downregulate receptors on the cell surface, decreasing cellular responsiveness.

The downregulation of receptor signaling reduced the cell's sensitivity to the hormone.

The new downregulator reduced inflammatory signaling in the cultured cells.

The study reported several unexpected downregulations in key signaling proteins after treatment.